Pfizer Adds Key Drug for Cancer in $14 Billion Deal

Pfizer agreed to buy biotech Medivation for about $14 billion, in a move that adds one of the crown jewels of the multibillion-dollar market for cancer drugs to Pfizer’s portfolio.

from WSJ.com: US Business http://ift.tt/2b9tKdl
via IFTTT